Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T22:41:58.607Z.
Calculation as of: 2026-10-06T22:41:58.607Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 84870b41b004d4a356f3546a7a12828ec10b1f950fc42869db9e2e4c5d55c05b
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$519.25M
PS Ratio
16749.86
TTM Avg
14908.47
3Y Avg
10316.98
5Y Avg
6997.34
Market Cap
$516.76M
PS Ratio
62.87
TTM Avg
55.76
3Y Avg
22.85
5Y Avg
49.57
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | $524.43M | N/A | N/A | N/A | N/A |
| Shattuck Labs, Inc. (STTK)vs › | $529.58M | 529.58 | 520.33 | 228.10 | 183.31 |
| Altimmune, Inc. (ALT)vs › | $519.25M | 16749.86 | 14908.47 | 10316.98 | 6997.34 |
| Nuvectis Pharma, Inc. (NVCT)vs › | $531.52M | N/A | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $531.98M | 5.58 | 5.23 | 17.66 | 17.71 |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $516.76M | 62.87 | 55.76 | 22.85 | 49.57 |
| Monopar Therapeutics Inc. (MNPR)vs › | $533.04M | N/A | N/A | N/A | N/A |
| ProKidney Corp. (PROK)vs › | $538.01M | 657.71 | 390.36 | 569.23 | 569.23 |
| 908 Devices Inc. (MASS)vs › | $505.87M | 8.31 | 4.86 | 4.00 | 6.89 |
| Crescent Biopharma, Inc. (CBIO)vs › | $504.04M | 42.42 | 40.07 | 1866.17 | 1168.37 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-07 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-25 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-07 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-07 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
